U.S. Peptide Regulation in 2026: A Researcher's Guide to the Current Landscape

Why This Matters for Researchers and Wholesale Buyers

The regulatory landscape for peptide compounds in the United States is one of the most active and contested areas of life-sciences law. For researchers and institutional buyers of research peptides, that complexity is not abstract — it directly shapes what you can buy, from whom, with what documentation, and under what labelling constraints.

This guide is a vendor-neutral overview of the framework as it stands in 2026, the recent developments that have reshaped it (particularly around GLP-1 compounds), and the trajectories worth watching. It is written for laboratory researchers, lab operations managers, and institutional procurement teams who order research peptides — not for clinicians or compounders, whose regulatory exposure is different.

Educational only — not legal advice. This article summarises publicly available regulatory information and is intended as a starting point for understanding the framework. It is not legal advice. For specific compliance questions affecting your laboratory, institution, or procurement workflow, consult qualified regulatory counsel.

Who Regulates What

Federal oversight of peptide compounds in the U.S. is distributed across several agencies, each with a different scope. Understanding which agency cares about which activity is the first step in reasoning about compliance.

FDA

Drugs

Approval, compounding, RUO labelling

DEA

Scheduling

Controlled substances classification

FTC

Marketing

Unfair / deceptive therapeutic claims

USP

Monographs

Compendial standards (non-binding)

CBP

Customs

Import labelling & documentation

States

Pharmacy

Compounding, telehealth, scheduling

The FDA

The Food and Drug Administration is the central regulator. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), any compound intended for therapeutic use in humans must go through FDA approval — typically a New Drug Application (NDA) or, for biological products, a Biologics License Application (BLA). Peptides that are not approved drugs cannot be lawfully sold, marketed, or distributed for therapeutic use.

The FDA's relevance to research-use-only peptide buyers is more indirect but still material:

Compounding rules (Sections 503A and 503B of the FD&C Act) govern when pharmacies or outsourcing facilities can prepare compounded peptide preparations from bulk active pharmaceutical ingredients.
Bulk Drug Substances list under 503A determines which substances are eligible for traditional pharmacy compounding.
Research-use-only (RUO) labelling — historically associated with in vitro diagnostics under 21 CFR 809.10 but applied more broadly in practice — provides the framework under which research peptides are lawfully supplied to qualified researchers.
Warning letters and enforcement actions are the FDA's primary public-facing signal of where current attention is focused.

The DEA

The Drug Enforcement Administration schedules controlled substances under the Controlled Substances Act (CSA). The vast majority of peptides marketed as research compounds — including the major GLP-1 receptor agonists, tissue-research peptides like BPC-157, and longevity-research compounds like Epithalon and MOTS-c — are not currently scheduled under federal law.

This is not a permanent guarantee. The DEA periodically reviews substances for scheduling consideration based on abuse potential and public health concerns. Researchers and buyers should treat the unscheduled status of specific compounds as accurate-as-of-shipment, not as a forever statement.

The FTC and DOJ

The Federal Trade Commission regulates marketing claims. The Department of Justice prosecutes cases referred from FDA, FTC, and other agencies. Both have been active in cases involving peptide products marketed with unsubstantiated therapeutic claims, particularly weight-loss and "anti-aging" marketing. Their relevance to research buyers is that suppliers using therapeutic marketing language are signalling a compliance posture that often correlates with other quality and documentation problems.

State Authorities

State pharmacy boards regulate licensed compounders within their state. States can also schedule substances independently of federal law, and several have done so for specific compounds in recent years. State telehealth statutes have become a major front in the broader peptide compounding debate — particularly for compounded GLP-1s.

The Research-Use-Only Framework

Most peptide compounds sold to laboratory researchers in the U.S. are supplied under a "research-use-only" (RUO) framework. This is not a single statute — it is a labelling and sale convention that exists at the intersection of FDA enforcement discretion, customs requirements, and the practical reality that there is legitimate scientific need for these compounds outside of FDA-approved drug supply.

Key elements of a compliant RUO supply chain:

Property	Compliant RUO posture	Compliance red flags
Labelling	"For laboratory research use only. Not for human consumption."	Therapeutic, dosing, or human-use language on packaging or marketing
Customer verification	Reasonable indicia of research purpose (institution, role, application)	Direct-to-consumer sale with no research-use representation
Documentation	Batch-specific Certificate of Analysis with HPLC, MS, third-party lab	Generic spec sheets, missing or self-issued COAs
Quality verification	≥98% HPLC purity verified before catalog listing	Purity claims without numerical methodology
Marketing	Scientific / research framing throughout	"Treatment cycles," dosing protocols, "therapy" language
Import documentation	Research-use declaration, COA, end-use information	Unlabelled bulk powder, vague country-of-origin

Compliance with this framework is a shared responsibility. The supplier is responsible for analytical verification, batch documentation, RUO labelling, and not crossing into therapeutic claims. The buyer is responsible for ensuring their use of research peptides is for laboratory purposes, complies with applicable federal/state/institutional regulations, and is consistent with the supplier's RUO terms.

For institutional buyers, this means following your institution's IBC, IRB, IACUC, and EH&S requirements as appropriate to your specific research. For independent labs and CROs, it means maintaining the same paper trail you would for any other research compound — purchase records, lot numbers, COA copies, and use logs.

The Compounding Landscape — and the GLP-1 Inflection

The most contested area of peptide regulation in the past two years has been pharmacy compounding of GLP-1 receptor agonists — particularly semaglutide and tirzepatide. This story is worth understanding because it illustrates how quickly the regulatory ground can shift, and because the precedents being set will likely apply to other peptide categories going forward.

503A and 503B Compounding — The Basics

Two sections of the FD&C Act govern compounded preparations:

Section 503A allows traditional pharmacy compounding for individual patients pursuant to a prescription. The substances used must either appear on the FDA's Bulk Drug Substances list, be a component of an FDA-approved drug, or be the subject of a USP monograph.
Section 503B governs outsourcing facilities, which can compound without patient-specific prescriptions but face more stringent quality and reporting requirements similar to drug manufacturers.

The Shortage Exception and Its End

When an FDA-approved drug is on the FDA's official shortage list, compounders can prepare copies of the approved product even if the active ingredient is not otherwise on the Bulk Drug Substances list. This created the legal basis for the explosion of compounded GLP-1 preparations from 2022 through 2024, when both semaglutide and tirzepatide were in declared shortage.

The FDA declared the semaglutide shortage resolved in October 2024 and the tirzepatide shortage resolved in February 2025, with phased enforcement deadlines triggering the wind-down of compounded supply. This was followed by litigation from outsourcing-facility trade associations challenging the FDA's shortage resolution determinations — litigation that has continued to shape the boundaries of compounding authority.

What This Means for Research Buyers

For laboratory researchers and wholesale buyers of research-use-only peptides, the compounding situation is largely a separate market. RUO peptides are not compounded preparations; they are research compounds supplied to qualified researchers under a different framework. The two markets are sometimes conflated in popular media, but they are legally and operationally distinct.

The relevance for research buyers is more about supplier signal: suppliers operating across both markets (selling RUO research peptides AND marketing compounded preparations to consumers or clinicians) are taking on a much higher compliance burden, and the boundary-blurring often shows up in their documentation quality and labelling discipline. Research buyers should look for suppliers whose entire operation is consistent with the RUO framework, not vendors straddling research and compounded therapeutics.

Recent Enforcement Trends

Enforcement signal is one of the most useful indicators of where regulatory attention is concentrated. Across 2024 and into 2025, several trends were observable in publicly available enforcement actions:

Therapeutic marketing claims: FDA warning letters to peptide marketers continued to focus on companies making explicit therapeutic, dosing, or human-use claims for research compounds. This is the most predictable category — therapeutic claims on a non-approved compound are a clear violation regardless of the underlying chemistry.
Direct-to-consumer sale framing: FTC and DOJ activity targeted companies marketing peptides through consumer-facing channels (social media, influencer marketing) without research-use framing.
Telehealth-prescribed compounded peptides: A separate enforcement front, particularly at the state pharmacy board level, has targeted telehealth platforms prescribing compounded peptides outside the normal patient-pharmacy relationship.
Import documentation: Customs enforcement of inadequately labelled or documented research peptide imports has been a persistent but lower-profile issue, particularly for international suppliers shipping to U.S. institutional buyers.

The signal across all of this is consistent: compliance with the research-use-only framework — accurate labelling, batch documentation, scientific-rather-than-therapeutic framing, and qualified-researcher distribution — is the through-line for suppliers that have not drawn enforcement attention.

What's on the Regulatory Horizon

The following are observable trajectories rather than firm 2026 predictions. Each is a known regulatory matter that has been publicly developing, where outcomes will likely materialise over the coming year or two:

Bulk Drug Substances list nominations: The FDA continues to evaluate substances nominated for inclusion on the 503A Bulk Drug Substances list. The composition of that list directly shapes what compounders can legally prepare, and the nomination process is one of the slower-moving but more consequential regulatory levers.
USP peptide monograph development: USP monograph status is a gatekeeper for compounding eligibility under 503A. Active monograph development for peptide compounds is ongoing and will continue to shape the regulatory boundary between compoundable and non-compoundable peptides.
Compounding litigation outcomes: The ongoing lawsuits from outsourcing-facility trade associations against the FDA's shortage-resolution determinations will produce judicial decisions that set precedent for how compounders, manufacturers, and the FDA can interact during future shortage periods.
State-level legislative activity: Multiple states have considered or enacted legislation affecting peptide telehealth prescribing, controlled substance scheduling, or pharmacy compounding rules. This activity is highly state-specific and likely to continue.
Federal interest in personalised medicine vs. industrialised compounding: Some Congressional interest has emerged in reconciling the traditional pharmacy compounding framework with the realities of modern telehealth and outsourcing-facility scale. Whether this materialises into new legislation is uncertain but worth tracking.

For research-use-only buyers specifically, none of these trajectories directly threatens RUO supply. The RUO framework is a separate channel from the compounding and approved-drug channels. The risk is indirect — heightened regulatory scrutiny across the broader peptide space can affect industry compliance norms, customs enforcement priorities, and supplier-side compliance investment.

Practical Compliance Practices for Research Labs

Regardless of how the regulatory landscape evolves, the following practices are consistent with the research-use-only framework as it currently exists and are worth building into any research peptide procurement workflow:

Maintain the paper trail. Purchase records, supplier COAs, lot numbers, and use logs should match across documentation. The COA on file should reference the same lot number printed on the vial. Institutional purchasers should follow their EH&S document retention requirements.
Verify the supplier's RUO posture. A compliant supplier's catalog, marketing, and packaging consistently use research-use language. Vendors that drift into therapeutic, dosing, or human-use language are taking on compliance risk that can reach upstream to your institution.
Confirm third-party verification. ISO 17025-accredited laboratory testing on every batch is the analytical chemistry standard. Self-issued COAs are not independent verification.
Follow your institutional research governance. IBC, IRB, IACUC, and EH&S requirements vary by institution and research scope. Research peptide procurement is generally not heavily controlled at the federal level, but institutional governance is independent of federal rules.
Stay current. The regulatory landscape is genuinely evolving. Subscribe to FDA Drug Shortage notifications, follow USP monograph announcements relevant to your compound classes, and maintain a relationship with regulatory counsel if your laboratory operates at scale.

How AQRO Research Operates Within This Framework

A short note on how we run our own operation, in the context of the framework above.

Every compound in our catalog is supplied as research-use-only. Every product page, every COA, every shipment label, and every package insert reflects that framework. We do not market or sell compounded preparations, telehealth-prescribed compounds, or any product framed for therapeutic or human use. The catalog is built for qualified researchers, and the entire operation — synthesis, third-party analytical verification, COA generation, packaging, and customer verification — runs on that single posture.

For the underlying quality framework — HPLC verification, mass spectrometry, ISO 17025 third-party testing, batch-specific Certificate of Analysis — see the Quality Standards page, the Peptide Buyer's Checklist, or our blog post on vetting research peptide suppliers.

Bottom Line

The U.S. regulatory framework for peptide compounds is layered, active, and worth understanding even if you are buying purely for laboratory research. The research-use-only channel — properly labelled, properly documented, properly distributed to qualified researchers — has been the stable through-line across two years of intense regulatory activity in the adjacent compounding space. Suppliers that operate consistently within that framework continue to serve research customers without the regulatory exposure that has affected the consumer-facing and compounding markets.

The most useful thing a research buyer or wholesale customer can do is to evaluate suppliers against the framework: are they labelling correctly, documenting properly, framing scientifically, and refusing to cross into therapeutic territory? That evaluation is something the Peptide Buyer's Checklist walks through directly.

Disclaimer. This article is provided for educational and informational purposes only. It is not legal advice and does not constitute a legal opinion on any specific factual situation. Regulatory rules and enforcement priorities can change without notice. For specific compliance questions affecting your laboratory, institution, procurement workflow, or supply arrangement, consult qualified regulatory counsel. AQRO Research does not provide legal or regulatory advice.